90 results on '"Vonk-Noordegraaf, Anton"'
Search Results
2. Chronic thromboembolic pulmonary hypertension and clot resolution after COVID-19-associated pulmonary embolism
- Author
-
de Jong, Cindy M.M., primary, Visser, Chantal, additional, Bemelmans, Remy H.H., additional, Boersma, Wim G., additional, van den Borst, Bram, additional, Burggraaf, J. Louise I., additional, Cannegieter, Suzanne C., additional, ten Cate-Hoek, Arina J., additional, Croles, F. Nanne, additional, Faber, Harald J., additional, Faber, Laura M., additional, Hellemons, Merel E., additional, Hessels, Lisa M., additional, Huisman, Menno V., additional, Kamphuisen, Pieter W., additional, Koster, Stephanie C.E., additional, Kroft, Lucia J.M., additional, van der Lee, Ivo, additional, Leentjens, Jenneke, additional, Meijer, Karina, additional, Ninaber, Maarten K., additional, Sondermeijer, Brigitte M., additional, Stads, Susanne, additional, Vonk Noordegraaf, Anton, additional, Winckers, Kristien, additional, Kruip, Marieke J.H.A., additional, and Klok, Frederikus A., additional
- Published
- 2023
- Full Text
- View/download PDF
3. Right atrial function is associated with RV diastolic stiffness: RA-RV interaction in pulmonary arterial hypertension
- Author
-
Wessels, Jeroen N., primary, Mouratoglou, Sophia A., additional, van Wezenbeek, Jessie, additional, Handoko, M. Louis, additional, Marcus, J. Tim, additional, Meijboom, Lilian J., additional, Westerhof, Berend E., additional, Jan Bogaard, Harm, additional, Strijkers, Gustav J., additional, Vonk Noordegraaf, Anton, additional, and de Man, Frances S., additional
- Published
- 2021
- Full Text
- View/download PDF
4. COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension
- Author
-
Hoeper, Marius M., primary, Pausch, Christine, additional, Olsson, Karen M., additional, Huscher, Doerte, additional, Pittrow, David, additional, Grünig, Ekkehard, additional, Staehler, Gerd, additional, Vizza, Carmine Dario, additional, Gall, Henning, additional, Distler, Oliver, additional, Opitz, Christian, additional, Gibbs, J. Simon R., additional, Delcroix, Marion, additional, Ghofrani, H. Ardeschir, additional, Park, Da-Hee, additional, Ewert, Ralf, additional, Kaemmerer, Harald, additional, Kabitz, Hans-Joachim, additional, Skowasch, Dirk, additional, Behr, Juergen, additional, Milger, Katrin, additional, Halank, Michael, additional, Wilkens, Heinrike, additional, Seyfarth, Hans-Jürgen, additional, Held, Matthias, additional, Dumitrescu, Daniel, additional, Tsangaris, Iraklis, additional, Vonk-Noordegraaf, Anton, additional, Ulrich, Silvia, additional, Klose, Hans, additional, Claussen, Martin, additional, Lange, Tobias J., additional, and Rosenkranz, Stephan, additional
- Published
- 2021
- Full Text
- View/download PDF
5. Temporal trends in pulmonary arterial hypertension: results from the COMPERA registry
- Author
-
Hoeper, Marius M., primary, Pausch, Christine, additional, Grünig, Ekkehard, additional, Staehler, Gerd, additional, Huscher, Doerte, additional, Pittrow, David, additional, Olsson, Karen M., additional, Vizza, Carmine Dario, additional, Gall, Henning, additional, Distler, Oliver, additional, Opitz, Christian, additional, Gibbs, J. Simon R., additional, Delcroix, Marion, additional, Ghofrani, H. Ardeschir, additional, Rosenkranz, Stephan, additional, Park, Da-Hee, additional, Ewert, Ralf, additional, Kaemmerer, Harald, additional, Lange, Tobias J., additional, Kabitz, Hans-Joachim, additional, Skowasch, Dirk, additional, Skride, Andris, additional, Claussen, Martin, additional, Behr, Juergen, additional, Milger, Katrin, additional, Halank, Michael, additional, Wilkens, Heinrike, additional, Seyfarth, Hans-Jürgen, additional, Held, Matthias, additional, Dumitrescu, Daniel, additional, Tsangaris, Iraklis, additional, Vonk-Noordegraaf, Anton, additional, Ulrich, Silvia, additional, and Klose, Hans, additional
- Published
- 2021
- Full Text
- View/download PDF
6. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
- Author
-
Humbert, Marc, Kovacs, Gabor, Hoeper, Marius M, Badagliacca, Roberto, Berger, Rolf MF, Brida, Margarita, Carlsen, Jørn, Coats, Andrew JS, Escribano-Subias, Pilar, Ferrari, Pisana, Ferreira, Diogenes S, Ghofrani, Hossein Ardeschir, Giannakoulas, George, Kiely, David G, Mayer, Eckhard, Meszaros, Gergely, Nagavci, Blin, Olsson, Karen M, Pepke-Zaba, Joanna, Quint, Jennifer K, Rådegran, Göran, Simonneau, Gerald, Sitbon, Olivier, Tonia, Thomy, Toshner, Mark, Vachiery, Jean-Luc, Vonk Noordegraaf, Anton, Delcroix, Marion, Rosenkranz, Stephan, ESC/ERS Scientific Document Group, Toshner, Mark [0000-0002-3969-6143], and Apollo - University of Cambridge Repository
- Subjects
Endothelin Receptor Antagonists ,Pulmonary and Respiratory Medicine ,lung disease ,diagnosis ,chronic thrombo-embolic pulmonary hypertension ,Hypertension, Pulmonary ,pulmonary endarterectomy ,prostacyclin receptor agonists ,guidelines ,treatment ,pulmonary hypertension ,left heart disease ,pulmonary arterial hypertension ,lung transplantation ,Humans ,610 Medicine & health ,Evidence-Based Medicine ,360 Soziale Probleme, Sozialdienste ,prostacyclin analogues ,congenital heart disease ,balloon pulmonary angioplasty ,connective tissue disease ,endothelin receptor antagonists ,phosphodiesterase type 5 inhibitors ,soluble guanylate cyclase stimulators ,Cardiology and Cardiovascular Medicine ,610 Medizin und Gesundheit ,Algorithms ,360 Social problems & social services - Published
- 2022
7. Evolution of CT findings after anticoagulant treatment for acute pulmonary embolism in patients with and without an ultimate diagnosis of chronic thromboembolic pulmonary hypertension
- Author
-
Braams, Natalia J., primary, Boon, Gudula J.A.M., additional, de Man, Frances S., additional, van Es, Josien, additional, den Exter, Paul L., additional, Kroft, Lucia J.M., additional, Beenen, Ludo F.M., additional, Huisman, Menno V., additional, Nossent, Esther J., additional, Boonstra, Anco, additional, Vonk Noordegraaf, Anton, additional, Ruigrok, Dieuwertje, additional, Klok, Frederikus A., additional, Bogaard, Harm Jan, additional, and Meijboom, Lilian J., additional
- Published
- 2021
- Full Text
- View/download PDF
8. Neurohormonal modulation in pulmonary arterial hypertension
- Author
-
Peters, Eva L., primary, Bogaard, Harm Jan, additional, Vonk Noordegraaf, Anton, additional, and de Man, Frances S., additional
- Published
- 2021
- Full Text
- View/download PDF
9. ERS statement on chronic thromboembolic pulmonary hypertension
- Author
-
Delcroix, Marion, primary, Torbicki, Adam, additional, Gopalan, Deepa, additional, Sitbon, Olivier, additional, Klok, Frederikus A., additional, Lang, Irene, additional, Jenkins, David, additional, Kim, Nick H., additional, Humbert, Marc, additional, Jais, Xavier, additional, Vonk Noordegraaf, Anton, additional, Pepke-Zaba, Joanna, additional, Brénot, Philippe, additional, Dorfmuller, Peter, additional, Fadel, Elie, additional, Ghofrani, Hossein-Ardeschir, additional, Hoeper, Marius M., additional, Jansa, Pavel, additional, Madani, Michael, additional, Matsubara, Hiromi, additional, Ogo, Takeshi, additional, Grünig, Ekkehard, additional, D'Armini, Andrea, additional, Galie, Nazzareno, additional, Meyer, Bernhard, additional, Corkery, Patrick, additional, Meszaros, Gergely, additional, Mayer, Eckhard, additional, and Simonneau, Gérald, additional
- Published
- 2020
- Full Text
- View/download PDF
10. Persistent exercise intolerance after pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension
- Author
-
Ruigrok, Dieuwertje, primary, Meijboom, Lilian J., additional, Nossent, Esther J., additional, Boonstra, Anco, additional, Braams, Natalia J., additional, van Wezenbeek, Jessie, additional, de Man, Frances S., additional, Marcus, J. Tim, additional, Vonk Noordegraaf, Anton, additional, Symersky, Petr, additional, and Bogaard, Harm-Jan, additional
- Published
- 2020
- Full Text
- View/download PDF
11. Correspondence regarding “T-box protein 4 mutation causing pulmonary arterial hypertension and lung disease”: a single-centre case series
- Author
-
Jansen, Samara M.A., primary, van den Heuvel, Lieke, additional, Meijboom, Lilian J., additional, Alsters, Suzanne I.M., additional, Vonk Noordegraaf, Anton, additional, Houweling, Arjan, additional, and Bogaard, Harm Jan, additional
- Published
- 2020
- Full Text
- View/download PDF
12. Severe Pulmonary Hypertension Management Across Europe (PHAROS): an ERS Clinical Research Collaboration
- Author
-
Sitbon, Olivier, primary, Reis, Abílio, additional, Humbert, Marc, additional, Vonk Noordegraaf, Anton, additional, and Delcroix, Marion, additional
- Published
- 2020
- Full Text
- View/download PDF
13. Vanishing vessels aboding pulmonary disease: a role for VEGFR2
- Author
-
Botros, Liza, primary, Vonk Noordegraaf, Anton, additional, and Aman, Jurjan, additional
- Published
- 2020
- Full Text
- View/download PDF
14. Vena cava backflow and right ventricular stiffness in pulmonary arterial hypertension
- Author
-
Marcus, J. Tim, primary, Westerhof, Berend E., additional, Groeneveldt, Joanne A., additional, Bogaard, Harm Jan, additional, de Man, Frances S., additional, and Vonk Noordegraaf, Anton, additional
- Published
- 2019
- Full Text
- View/download PDF
15. Prevention of progression of pulmonary hypertension by the Nur77 agonist 6-mercaptopurine: role of BMP signalling
- Author
-
Kurakula, Kondababu, primary, Sun, Xiao-Qing, additional, Happé, Chris, additional, da Silva Goncalves Bos, Denielli, additional, Szulcek, Robert, additional, Schalij, Ingrid, additional, Wiesmeijer, Karien C., additional, Lodder, Kirsten, additional, Tu, Ly, additional, Guignabert, Christophe, additional, de Vries, Carlie J.M., additional, de Man, Frances S., additional, Vonk Noordegraaf, Anton, additional, ten Dijke, Peter, additional, Goumans, Marie-José, additional, and Bogaard, Harm Jan, additional
- Published
- 2019
- Full Text
- View/download PDF
16. The unknown pathophysiological relevance of right ventricular hypertrophy in pulmonary arterial hypertension
- Author
-
de Man, Frances S., primary, Handoko, M. Louis, additional, and Vonk-Noordegraaf, Anton, additional
- Published
- 2019
- Full Text
- View/download PDF
17. Pathophysiology of the right ventricle and of the pulmonary circulation in pulmonary hypertension: an update
- Author
-
Vonk Noordegraaf, Anton, primary, Chin, Kelly Marie, additional, Haddad, François, additional, Hassoun, Paul M., additional, Hemnes, Anna R., additional, Hopkins, Susan Roberta, additional, Kawut, Steven Mark, additional, Langleben, David, additional, Lumens, Joost, additional, and Naeije, Robert, additional
- Published
- 2019
- Full Text
- View/download PDF
18. ERS statement on exercise training and rehabilitation in patients with severe chronic pulmonary hypertension
- Author
-
Grünig, Ekkehard, primary, Eichstaedt, Christina, additional, Barberà, Joan-Albert, additional, Benjamin, Nicola, additional, Blanco, Isabel, additional, Bossone, Eduardo, additional, Cittadini, Antonio, additional, Coghlan, Gerry, additional, Corris, Paul, additional, D'Alto, Michele, additional, D'Andrea, Antonello, additional, Delcroix, Marion, additional, de Man, Frances, additional, Gaine, Sean, additional, Ghio, Stefano, additional, Gibbs, Simon, additional, Gumbiene, Lina, additional, Howard, Luke S., additional, Johnson, Martin, additional, Jurevičienė, Elena, additional, Kiely, David G., additional, Kovacs, Gabor, additional, MacKenzie, Alison, additional, Marra, Alberto M., additional, McCaffrey, Noel, additional, McCaughey, Paul, additional, Naeije, Robert, additional, Olschewski, Horst, additional, Pepke-Zaba, Joanna, additional, Reis, Abílio, additional, Santos, Mário, additional, Saxer, Stéphanie, additional, Tulloh, Robert M., additional, Ulrich, Silvia, additional, Vonk Noordegraaf, Anton, additional, and Peacock, Andrew J., additional
- Published
- 2018
- Full Text
- View/download PDF
19. Risk assessment in medically treated chronic thromboembolic pulmonary hypertension patients
- Author
-
Delcroix, Marion, primary, Staehler, Gerd, additional, Gall, Henning, additional, Grünig, Ekkehard, additional, Held, Matthias, additional, Halank, Michael, additional, Klose, Hans, additional, Vonk-Noordegraaf, Anton, additional, Rosenkranz, Stephan, additional, Pepke-Zaba, Joanna, additional, Opitz, Christian F., additional, Gibbs, J. Simon R., additional, Lange, Tobias J., additional, Tsangaris, Iraklis, additional, Huscher, Doerte, additional, Pittrow, David, additional, Olsson, Karen M., additional, and Hoeper, Marius M., additional
- Published
- 2018
- Full Text
- View/download PDF
20. Balloon pulmonary angioplasty in sarcoid-related pulmonary hypertension
- Author
-
Tramper, Jelco, primary, Nossent, Esther J., additional, Lely, Rutger J., additional, Krouwels, Frans H., additional, Meijboom, Lilian J., additional, and Vonk Noordegraaf, Anton, additional
- Published
- 2018
- Full Text
- View/download PDF
21. An official European Respiratory Society statement: pulmonary haemodynamics during exercise
- Author
-
Kovacs, Gabor, primary, Herve, Philippe, additional, Barbera, Joan Albert, additional, Chaouat, Ari, additional, Chemla, Denis, additional, Condliffe, Robin, additional, Garcia, Gilles, additional, Grünig, Ekkehard, additional, Howard, Luke, additional, Humbert, Marc, additional, Lau, Edmund, additional, Laveneziana, Pierantonio, additional, Lewis, Gregory D., additional, Naeije, Robert, additional, Peacock, Andrew, additional, Rosenkranz, Stephan, additional, Saggar, Rajeev, additional, Ulrich, Silvia, additional, Vizza, Dario, additional, Vonk Noordegraaf, Anton, additional, and Olschewski, Horst, additional
- Published
- 2017
- Full Text
- View/download PDF
22. Vascular remodelling in the pulmonary circulation after major lung resection
- Author
-
Rol, Nina, primary, Happé, Chris, additional, Beliën, Jeroen A.M., additional, de Man, Frances S., additional, Westerhof, Nico, additional, Vonk-Noordegraaf, Anton, additional, Grünberg, Katrien, additional, and Bogaard, Harm J., additional
- Published
- 2017
- Full Text
- View/download PDF
23. Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model
- Author
-
Hoeper, Marius M., primary, Kramer, Tilmann, additional, Pan, Zixuan, additional, Eichstaedt, Christina A., additional, Spiesshoefer, Jens, additional, Benjamin, Nicola, additional, Olsson, Karen M., additional, Meyer, Katrin, additional, Vizza, Carmine Dario, additional, Vonk-Noordegraaf, Anton, additional, Distler, Oliver, additional, Opitz, Christian, additional, Gibbs, J. Simon R., additional, Delcroix, Marion, additional, Ghofrani, H. Ardeschir, additional, Huscher, Doerte, additional, Pittrow, David, additional, Rosenkranz, Stephan, additional, and Grünig, Ekkehard, additional
- Published
- 2017
- Full Text
- View/download PDF
24. Upfront combination therapy reduces right ventricular volumes in pulmonary arterial hypertension
- Author
-
van de Veerdonk, Mariëlle C., primary, Huis in t Veld, Anna E., additional, Marcus, J. Tim, additional, Westerhof, Nico, additional, Heymans, Martijn W., additional, Bogaard, Harm-Jan, additional, and Vonk-Noordegraaf, Anton, additional
- Published
- 2017
- Full Text
- View/download PDF
25. Incidence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: a contemporary view of the published literature
- Author
-
Ende-Verhaar, Yvonne M., primary, Cannegieter, Suzanne C., additional, Vonk Noordegraaf, Anton, additional, Delcroix, Marion, additional, Pruszczyk, Piotr, additional, Mairuhu, Albert T.A., additional, Huisman, Menno V., additional, and Klok, Frederikus A., additional
- Published
- 2017
- Full Text
- View/download PDF
26. A randomised controlled trial on the effect of inhaled hypertonic saline on quality of life in primary ciliary dyskinesia
- Author
-
Paff, Tamara, primary, Daniels, Johannes M.A., additional, Weersink, Els J., additional, Lutter, René, additional, Vonk Noordegraaf, Anton, additional, and Haarman, Eric G., additional
- Published
- 2017
- Full Text
- View/download PDF
27. Bisoprolol in idiopathic pulmonary arterial hypertension: an explorative study
- Author
-
van Campen, Jasmijn S.J.A., primary, de Boer, Karin, additional, van de Veerdonk, Mariëlle C., additional, van der Bruggen, Cathelijne E.E., additional, Allaart, Cor P., additional, Raijmakers, Pieter G., additional, Heymans, Martijn W., additional, Marcus, J. Tim, additional, Harms, Hendrik J., additional, Handoko, M. Louis, additional, de Man, Frances S., additional, Vonk Noordegraaf, Anton, additional, and Bogaard, Harm-Jan, additional
- Published
- 2016
- Full Text
- View/download PDF
28. Exercise-induced pulmonary hypertension: at last!
- Author
-
Naeije, Robert, primary, Vonk Noordegraaf, Anton, additional, and Kovacs, Gabor, additional
- Published
- 2015
- Full Text
- View/download PDF
29. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
- Author
-
Galiè, Nazzareno, primary, Humbert, Marc, additional, Vachiery, Jean-Luc, additional, Gibbs, Simon, additional, Lang, Irene, additional, Torbicki, Adam, additional, Simonneau, Gérald, additional, Peacock, Andrew, additional, Vonk Noordegraaf, Anton, additional, Beghetti, Maurice, additional, Ghofrani, Ardeschir, additional, Gomez Sanchez, Miguel Angel, additional, Hansmann, Georg, additional, Klepetko, Walter, additional, Lancellotti, Patrizio, additional, Matucci, Marco, additional, McDonagh, Theresa, additional, Pierard, Luc A., additional, Trindade, Pedro T., additional, Zompatori, Maurizio, additional, and Hoeper, Marius, additional
- Published
- 2015
- Full Text
- View/download PDF
30. The striated muscles in pulmonary arterial hypertension: adaptations beyond the right ventricle
- Author
-
Manders, Emmy, primary, Rain, Silvia, additional, Bogaard, Harm-Jan, additional, Handoko, M. Louis, additional, Stienen, Ger J.M., additional, Vonk-Noordegraaf, Anton, additional, Ottenheijm, Coen A.C., additional, and de Man, Frances S., additional
- Published
- 2015
- Full Text
- View/download PDF
31. Clinical relevance of right ventricular diastolic stiffness in pulmonary hypertension
- Author
-
Trip, Pia, primary, Rain, Silvia, additional, Handoko, M. Louis, additional, van der Bruggen, Cathelijne, additional, Bogaard, Harm J., additional, Marcus, J. Tim, additional, Boonstra, Anco, additional, Westerhof, Nico, additional, Vonk-Noordegraaf, Anton, additional, and de Man, Frances S., additional
- Published
- 2015
- Full Text
- View/download PDF
32. Noninvasive identification of left-sided heart failure in a population suspected of pulmonary arterial hypertension
- Author
-
Jacobs, Wouter, primary, Konings, Thelma C., additional, Heymans, Martijn W., additional, Boonstra, Anco, additional, Bogaard, Harm Jan, additional, van Rossum, Albert C., additional, and Vonk Noordegraaf, Anton, additional
- Published
- 2015
- Full Text
- View/download PDF
33. Quadriceps muscle fibre dysfunction in patients with pulmonary arterial hypertension
- Author
-
Manders, Emmy, primary, Ruiter, Gerrina, additional, Bogaard, Harm-Jan, additional, Stienen, Ger J.M., additional, Vonk-Noordegraaf, Anton, additional, de Man, Frances S., additional, and Ottenheijm, Coen A.C., additional
- Published
- 2015
- Full Text
- View/download PDF
34. Sildenafil: a definitive NO in COPD
- Author
-
Vonk-Noordegraaf, Anton, primary and Boerrigter, Bart G., additional
- Published
- 2013
- Full Text
- View/download PDF
35. Dasatinib-induced pulmonary arterial hypertension unresponsive to PDE-5 inhibition
- Author
-
Groeneveldt, Joanne A., primary, Gans, Steven J.M., additional, Bogaard, Harm J., additional, and Vonk-Noordegraaf, Anton, additional
- Published
- 2013
- Full Text
- View/download PDF
36. Severely reduced diffusion capacity in idiopathic pulmonary arterial hypertension: patient characteristics and treatment responses
- Author
-
Trip, Pia, primary, Nossent, Esther J., additional, de Man, Frances S., additional, van den Berk, Inge A.H., additional, Boonstra, Anco, additional, Groepenhoff, Herman, additional, Leter, Edward M., additional, Westerhof, Nico, additional, Grünberg, Katrien, additional, Bogaard, Harm-Jan, additional, and Vonk-Noordegraaf, Anton, additional
- Published
- 2013
- Full Text
- View/download PDF
37. Reversibility of the monocrotaline pulmonary hypertension rat model
- Author
-
Ruiter, Gerrina, primary, de Man, Frances S., additional, Schalij, Ingrid, additional, Sairras, Shellice, additional, Grünberg, Katrien, additional, Westerhof, Nico, additional, van der Laarse, Willem J., additional, and Vonk-Noordegraaf, Anton, additional
- Published
- 2013
- Full Text
- View/download PDF
38. Describing right ventricular function
- Author
-
Vonk-Noordegraaf, Anton, primary and Westerhof, Nico, additional
- Published
- 2013
- Full Text
- View/download PDF
39. Major bleeding with vitamin K antagonist anticoagulants in pulmonary hypertension
- Author
-
Henkens, Ivo R., primary, Hazenoot, Thomas, additional, Boonstra, Anco, additional, Huisman, Menno V., additional, and Vonk-Noordegraaf, Anton, additional
- Published
- 2012
- Full Text
- View/download PDF
40. Pathophysiology of the right ventricle and its pulmonary vascular interaction.
- Author
-
Hemnes AR, Celermajer DS, D'Alto M, Haddad F, Hassoun PM, Prins KW, Naeije R, and Vonk Noordegraaf A
- Abstract
The right ventricle and its stress response is perhaps the most important arbiter of survival in patients with pulmonary hypertension of many causes. The physiology of the cardiopulmonary unit and definition of right heart failure proposed in the 2018 World Symposium on Pulmonary Hypertension have proven useful constructs in subsequent years. Here, we review updated knowledge of basic mechanisms that drive right ventricular function in health and disease, and which may be useful for therapeutic intervention in the future. We further contextualise new knowledge on assessment of right ventricular function with a focus on metrics readily available to clinicians and updated understanding of the roles of the right atrium and tricuspid regurgitation. Typical right ventricular phenotypes in relevant forms of pulmonary vascular disease are reviewed and recent studies of pharmacological interventions on chronic right ventricular failure are discussed. Finally, unanswered questions and future directions are proposed., Competing Interests: Conflict of interest: A.R. Hemnes reports grants from NIH/NHLBI, consultancy fees from Bayer, Gossamer Bio, Merck, Janssen, United Therapeutics and Tenax, participation on a data safety monitoring board or advisory board with NIH/NHLBI, leadership roles with Nashville Ballet and Pulmonary Vascular Research Institute, and stock (or stock options) with Tenax Therapeutics. D.S. Celermajer has no potential conflicts of interest to disclose. M. D'Alto reports consultancy fees and payment or honoraria for lectures, presentations, manuscript writing or educational events from Merck Sharp and Dhome, Dompé, AOP and Janssen, and support for attending meetings from Dompé, AOP and Janssen. F. Haddad reports grants from Johnson & Johnson, and consultancy fees from Merck. P.M. Hassoun reports grants from NIH/NHLBI (R01 R01HL114910), and participation on a data safety monitoring board or advisory board with MSD and ARIA-CV. K.W. Prins reports grants from NHLBI (R01 HL158795 and 162927) and Bayer (PHAB grant), and consultancy fees from Edwards. R. Naeije reports consultancy fees from AOP Orphan Pharma, Johnson & Johnson, United Therapeutics and Lung Biotechnology, payment or honoraria for lectures, presentations, manuscript writing or educational events from AOP Orphan Pharma, support for attending meetings from AOP Orphan Pharma, and participation on a data safety monitoring board or advisory board with Johnson&Johnson, AOP Orphan Pharma and United Therapeutics. A. Vonk Noordegraaf reports payment or honoraria for lectures, presentations, manuscript writing or educational events from Actelion and Johnson & Johnson., (Copyright ©The authors 2024.)
- Published
- 2024
- Full Text
- View/download PDF
41. Deep phenotyping of unaffected carriers of pathogenic BMPR2 variants screened for pulmonary arterial hypertension.
- Author
-
Tóth EN, Celant LR, Niglas M, Jansen S, Tramper J, Baxan N, Ashek A, Wessels JN, Marcus JT, Meijboom LJ, Houweling AC, Nossent EJ, Aman J, Grynblat J, Perros F, Montani D, Vonk Noordegraaf A, Zhao L, de Man FS, and Bogaard HJ
- Abstract
Introduction: Pathogenic variants in the gene encoding for BMPR2 are a major genetic risk factor for heritable pulmonary arterial hypertension (PAH). Due to incomplete penetrance, deep-phenotyping of unaffected carriers (UCs) of a pathogenic BMPR2 variant through multi-modality screening may aid in early diagnosis and identify susceptibility traits for future development of PAH., Methods: 28 UCs (44±16 years, 57% female) and 21 healthy controls (43±18 years, 48% female) underwent annual screening, including cardiac magnetic resonance imaging (cMRI), transthoracic echocardiography (TTE), cardiopulmonary exercise testing (CPET) and right heart catheterization (RHC). Right ventricular (RV) pressure-volume (PV) loops were constructed to assess load independent contractility and compared with a healthy control group. A transgenic Bmpr2
Δ71Ex1/+ rat model was employed to validate findings in humans., Results: UCs had lower indexed right ventricular end-diastolic (80±18 mL·m-2 versus 64±14 mL·m-2 ;p= 0.003), end-systolic (34±11 mL·m-2 versus 27±8 mL·m-2 ;p=0.024) and left end-diastolic volumes (69±14 mL·m-2 versus 60±11 mL·m-2 ;p=0.019) than control subjects. Bmpr2Δ71Ex1/+ rats were also observed to have smaller cardiac volumes than WT rats. PV loop analysis showed significantly higher afterload (Ea) (0.15±0.06 versus 0.27±0.08; p<0.001), and end-systolic elastance (Ees) 0.28±0.07 versus 0.35±0.10; p=0.047) in addition to lower RV-pulmonary artery coupling (Ees/Ea)(2.24±1.03 versus 1.36±0.37; p=0.006) in UCs. During the 4-year follow-up period, two UCs developed PAH with normal NT-proBNP and TTE indices at diagnosis., Conclusion: Unaffected BMPR2 mutation carriers have an altered cardiac phenotype mimicked in Bmpr2Δ71Ex1/+ transgenic rats. Future efforts in establishing an effective screening protocol for individuals at risk for developing PAH warrants longer follow-up periods., (Copyright ©The authors 2024. For reproduction rights and permissions contact permissions@ersnet.org.)- Published
- 2024
- Full Text
- View/download PDF
42. Optimisation of detecting chronic thromboembolic pulmonary hypertension in acute pulmonary embolism survivors: the InShape IV study.
- Author
-
Luijten D, Valerio L, Boon GJAM, Barco S, Bogaard HJ, Delcroix M, Ende-Verhaar Y, Huisman MV, Jara-Palomares L, Kreitner KF, Kroft LJM, Mairuhu AT, Mavromanoli AC, Meijboom LJ, van Mens TE, Ninaber MK, Nossent EJ, Pruszczyk P, Rosenkranz S, Vliegen H, Vonk Noordegraaf A, Konstantinides SV, and Klok FA
- Abstract
Introduction: Chronic thromboembolic pulmonary hypertension (CTEPH) is often diagnosed late in acute pulmonary embolism (PE) survivors: more efficient testing to expedite diagnosis may considerably improve patient outcomes. The InShape II algorithm safely rules out CTEPH (failure rate 0.29%) while requiring echocardiography in only 19% of patients but may be improved by adding detailed reading of the computed tomography pulmonary angiography (CTPA) diagnosing the index PE., Methods: Twelve new algorithms, incorporating the CTEPH prediction score, ECG reading, NT-proBNP levels and dedicated CTPA reading were evaluated in the international InShape II (n=341) and part of the German FOCUS cohort (n=171). Evaluation criteria included failure rate, defined as the incidence of confirmed CTEPH in PE patients in whom echocardiography was deemed unnecessary by the algorithm, and the overall net reclassification index (NRI) compared to the InShape II algorithm., Results: The algorithm starting with CTPA reading of the index PE for 6 signs of CTEPH, followed by the ECG/NTproBNP assessment and echocardiography resulted in the most beneficial change compared to InShape II with a need for echocardiography in 20% (+5%), a failure rate of 0%, and an NRI of +3.5, reflecting improved performance over the InShape II algorithm. In the FOCUS cohort, this approach lowered echocardiography need to 24% (-6%) and missed no CTEPH cases, with an NRI of +6.0., Conclusion: Dedicated CTPA reading of the index PE improved the performance of the InShape II algorithm and may improve the selection of PE survivors who require echocardiography to rule out CTEPH., (Copyright ©The authors 2024. For reproduction rights and permissions contact permissions@ersnet.org.)
- Published
- 2024
- Full Text
- View/download PDF
43. Tricuspid regurgitation in pulmonary arterial hypertension: a right ventricular volumetric and functional analysis.
- Author
-
Yoshida K, van Wezenbeek J, Wessels JN, de Man FS, Sunagawa K, Vonk-Noordegraaf A, and Bogaard HJ
- Subjects
- Humans, Female, Male, Middle Aged, Adult, Stroke Volume, Heart Ventricles physiopathology, Heart Ventricles diagnostic imaging, Pulmonary Artery physiopathology, Prognosis, Aged, Tricuspid Valve physiopathology, Tricuspid Valve diagnostic imaging, Ventricular Dysfunction, Right physiopathology, Ventricular Dysfunction, Right diagnostic imaging, Magnetic Resonance Imaging, Hypertension, Pulmonary physiopathology, Natriuretic Peptide, Brain blood, Tricuspid Valve Insufficiency physiopathology, Tricuspid Valve Insufficiency complications, Pulmonary Arterial Hypertension physiopathology, Pulmonary Arterial Hypertension complications, Ventricular Function, Right
- Abstract
Background: The consequences of tricuspid regurgitation (TR) for right ventricular (RV) function and prognosis in pulmonary arterial hypertension (PAH) are poorly described and effects of tricuspid valve repair on the RV are difficult to predict., Methods: In 92 PAH patients with available cardiac magnetic resonance (CMR) studies, TR volume was calculated as the difference between RV stroke volume and forward stroke volume, i.e. pulmonary artery (PA) stroke volume. Survival was estimated from the time of the CMR scan to cardiopulmonary death or lung transplantation. In a subgroup, pressure-volume loop analysis including two-parallel elastances was applied to evaluate effective elastances, including net afterload (effective arterial elastance ( E
a )), forward afterload (effective pulmonary arterial elastance ( Epa )) and backward afterload (effective tricuspid regurgitant elastance ( ETR )). The effects of tricuspid valve repair were simulated using the online software package Harvi., Results: 26% of PAH patients had a TR volume ≥30 mL. Greater TR volume was associated with increased N-terminal pro-brain natriuretic peptide (p=0.018), mean right atrial pressure (p<0.001) and RV end-systolic and -diastolic volume (both p<0.001). TR volume ≥30 mL was associated with a poor event-free survival (p=0.008). In comparison to Ea , Epa correlated better with indices of RV dysfunction. Lower end-systolic elastance ( Ees ) (p=0.002) and ETR (p=0.030), higher Epa (p=0.001) and reduced Ees / Epa (p<0.001) were found in patients with a greater TR volume. Simulations predicted that tricuspid valve repair increases RV myocardial oxygen consumption in PAH patients with severe TR and low Ees unless aggressive volume reduction is accomplished., Conclusions: In PAH, TR has prognostic significance and is associated with low RV contractility and RV-PA uncoupling. However, haemodynamic simulations showed detrimental consequences of tricuspid valve repair in PAH patients with low RV contractility., Competing Interests: Conflict of interest: H.J. Bogaard received research grants and lecture fees from Janssen Pharmaceuticals and MSD, and serves on an advisory board for Novartis. The remaining authors have no potential conflicts of interest to disclose., (Copyright ©The authors 2024. For reproduction rights and permissions contact permissions@ersnet.org.)- Published
- 2024
- Full Text
- View/download PDF
44. Incidence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: an updated systematic review and meta-analysis.
- Author
-
Luijten D, Talerico R, Barco S, Cannegieter SC, Delcroix M, Ende-Verhaar YM, Huisman MV, Konstantinidis S, Mairuhu ATA, van Mens TE, Ninaber M, Pruszczyk P, Vonk Noordegraaf A, and Klok FA
- Subjects
- Humans, Incidence, Acute Disease, Chronic Disease, Hypertension, Pulmonary complications, Hypertension, Pulmonary epidemiology, Thromboembolism complications, Pulmonary Embolism complications, Pulmonary Embolism epidemiology
- Abstract
Competing Interests: Conflict of interest: The authors have no potential conflicts of interest to disclose.
- Published
- 2023
- Full Text
- View/download PDF
45. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.
- Author
-
Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, Carlsen J, Coats AJS, Escribano-Subias P, Ferrari P, Ferreira DS, Ghofrani HA, Giannakoulas G, Kiely DG, Mayer E, Meszaros G, Nagavci B, Olsson KM, Pepke-Zaba J, Quint JK, Rådegran G, Simonneau G, Sitbon O, Tonia T, Toshner M, Vachiery JL, Vonk Noordegraaf A, Delcroix M, and Rosenkranz S
- Subjects
- Humans, Evidence-Based Medicine, Algorithms, Hypertension, Pulmonary diagnosis, Hypertension, Pulmonary therapy
- Published
- 2023
- Full Text
- View/download PDF
46. Unbowed, unbent, unbroken: predicting pulmonary hypertension using echocardiography.
- Author
-
van de Veerdonk MC, Vonk-Noordegraaf A, and Vachiery JL
- Subjects
- Echocardiography, Humans, Probability, Pulmonary Artery physiopathology, Hypertension, Pulmonary diagnostic imaging, Hypertension, Pulmonary physiopathology
- Abstract
Competing Interests: Conflict of interest: M.C. van de Veerdonk reports no conflict of interest. Conflict of interest: A. Vonk-Noordegraaf declares no conflict of interest for this manuscript. A. Vonk Noordegraaf is supported by the Netherlands CardioVascular Research Initiative (CVON-2012-08 PHAEDRA, CVON-2017-10 DOLPHIN-GENESIS) and the Netherlands Organization for Scientific Research (NWO-VICI: 918.16.610). In addition, his institute received speakers money from Johnson & Johnson, MSD, Actelion, Bayer and Ferrer in the past 3 years. Finally, he served as a member of the scientific advisory board of Morphogen-X, Ferrer and Johnson & Johnson. Conflict of interest: J-L. Vachiery declares no conflict of interest for this work. He is the holder of the Janssen Chair for research in pulmonary hypertension at his institution.
- Published
- 2022
- Full Text
- View/download PDF
47. COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension.
- Author
-
Hoeper MM, Pausch C, Olsson KM, Huscher D, Pittrow D, Grünig E, Staehler G, Vizza CD, Gall H, Distler O, Opitz C, Gibbs JSR, Delcroix M, Ghofrani HA, Park DH, Ewert R, Kaemmerer H, Kabitz HJ, Skowasch D, Behr J, Milger K, Halank M, Wilkens H, Seyfarth HJ, Held M, Dumitrescu D, Tsangaris I, Vonk-Noordegraaf A, Ulrich S, Klose H, Claussen M, Lange TJ, and Rosenkranz S
- Subjects
- Familial Primary Pulmonary Hypertension, Humans, Natriuretic Peptide, Brain, Peptide Fragments, Registries, Risk Assessment, Hypertension, Pulmonary, Pulmonary Arterial Hypertension diagnosis
- Abstract
Background: Risk stratification plays an essential role in the management of patients with pulmonary arterial hypertension (PAH). The current European guidelines propose a three-stratum model to categorise risk as low, intermediate or high, based on the expected 1-year mortality. However, with this model, most patients are categorised as intermediate risk. We investigated a modified approach based on four risk categories, with intermediate risk subdivided into intermediate-low and intermediate-high risk., Methods: We analysed data from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA), a European pulmonary hypertension registry, and calculated risk at diagnosis and first follow-up based on World Health Organization functional class, 6-min walk distance (6MWD) and serum levels of brain natriuretic peptide (BNP) or N-terminal pro-BNP (NT-proBNP), using refined cut-off values. Survival was assessed using Kaplan-Meier analyses, log-rank testing and Cox proportional hazards models., Results: Data from 1655 patients with PAH were analysed. Using the three-stratum model, most patients were classified as intermediate risk (76.0% at baseline and 63.9% at first follow-up). The refined four-stratum risk model yielded a more nuanced separation and predicted long-term survival, especially at follow-up assessment. Changes in risk from baseline to follow-up were observed in 31.1% of the patients with the three-stratum model and in 49.2% with the four-stratum model. These changes, including those between the intermediate-low and intermediate-high strata, were associated with changes in long-term mortality risk., Conclusions: Modified risk stratification using a four-stratum model based on refined cut-off levels for functional class, 6MWD and BNP/NT-proBNP was more sensitive to prognostically relevant changes in risk than the original three-stratum model., Competing Interests: Conflict of interest: M.M. Hoeper has received fees for lectures and/or consultations from Acceleron, Actelion, Bayer, GSK, Janssen, MSD and Pfizer. Conflict of interest: C. Pausch has nothing to disclose. Conflict of interest: K.M. Olsson has received fees for lectures and/or consultations from Acceleron, Actelion, Bayer, GSK, Janssen, MSD, Pfizer and United Therapeutics. Conflict of interest: D. Huscher has received travel compensation from Shire. Conflict of interest: D. Pittrow has received fees for consultations from Actelion, Amgen, Aspen, Bayer, Biogen, Boehringer Ingelheim, Daiichi Sankyo, MSD, Novartis, Sanofi-Genzyme, Takeda and Viatris. Conflict of interest: E. Grünig has received fees for lectures and/or consultations from Actelion, Bayer, GSK, Janssen, MSD, Pfizer and United Therapeutics. Conflict of interest: G. Staehler has received honoraria for lectures and/or consultancy for Actelion, Bayer, GSK, Novartis and Pfizer. Conflict of interest: C.D. Vizza has received fees for lectures and/or consultations from Acceleron, Actelion, Bayer, GSK, Janssen, MSD, Pfizer and United Therapeutics. Conflict of interest: H. Gall reports personal fees from Actelion, AstraZeneca, Bayer, BMS, GSK, Janssen-Cilag, Lilly, MSD, Novartis, OMT, Pfizer and United Therapeutics. Conflict of interest: O. Distler has/had consultancy relationship and/or has received research funding from 4 D Science, Actelion, Active Biotec, Bayer, Biogen Idec, Boehringer Ingelheim Pharma, BMS, ChemoAb, EpiPharm, Ergonex, espeRare foundation, GSK, Genentech/Roche, Inventiva, Janssen, Lilly, medac, MedImmune, Mitsubishi Tanabe, Pharmacyclics, Pfizer, Sanofi, Serodapharm and Sinoxa in the area of potential treatments of scleroderma and its complications including PAH; and has a patent mir-29 for the treatment of systemic sclerosis licensed. Conflict of interest: C. Opitz has nothing to disclose. Conflict of interest: J.S.R. Gibbs has received fees for lectures and/or consultations from Acceleron, Actelion, Aerovate, Bayer, Complexia, Janssen, MSD, Pfizer and United Therapeutics. Conflict of interest: M. Delcroix reports research grants from Actelion/J&J, speaker and consultant fees from Bayer, MSD, Acceleron, AOP and Daiichi Sankyo, outside the submitted work; and is holder of the Janssen Chair for Pulmonary Hypertension at the KU Leuven. Conflict of interest: H.A. Ghofrani has received honoraria for consultations and/or speaking at conferences from Bayer HealthCare AG, Actelion, Encysive, Pfizer, Ergonex, Lilly and Novartis; is member of advisory boards for Acceleron, Bayer HealthCare AG, Pfizer, GSK, Actelion, Lilly, Merck, Encysive and Ergonex; has received governmental grants from the German Research Foundation (DFG), Excellence Cluster Cardiopulmonary Research (ECCPS), State Government of Hessen (LOEWE) and the German Ministry for Education and Research (BMBF). Conflict of interest: D-H. Park has nothing to disclose. Conflict of interest: R. Ewert has received speaker fees and honoraria for consultations from Actelion, Bayer, GSK, Janssen, Lilly, MSD, Novartis, Pfizer and United Therapeutics. Conflict of interest: H. Kaemmerer has received honoraria for lectures and/or consultancy from Actelion, Bristol Myers Squibb and Janssen. Conflict of interest: H-J. Kabitz has received fees from Löwenstein Medical, Weinmann, Philips Respironics, ResMed, Vivisol, Sapio Life and Sanofi-Genzyme. Conflict of interest: D. Skowasch received fees for lectures and/or consulting and/or research support (paid to institution) from Actelion, Bayer, GSK, Janssen, MSD and Pfizer. Conflict of interest: J. Behr received grants from Actelion, Bayer, Biogen, Boehringer Ingelheim, Galapagos, Novartis, Roche and Sanofi/Genzyme. Conflict of interest: K. Milger has received fees from Actelion, AstraZeneca, GSK, Janssen, MSD, Novartis and Sanofi-Aventis. Conflict of interest: M. Halank has received speaker fees and honoraria for consultations from Acceleron, Actelion, AstraZeneca, Bayer, BerlinChemie, GSK, Janssen and Novartis. Conflict of interest: H. Wilkens received fees for lectures and/or consultations from Actelion, Bayer, Biotest, Boehringer, GSK, Janssen, Pfizer and Roche. Conflict of interest: H-J. Seyfarth has received speaker fees and honoraria for consultations from Actelion, Bayer, GSK, Janssen and MSD. Conflict of interest: M. Held has received speaker fees and honoraria for consultations from Actelion, Bayer, Boehringer Ingelheim Pharma, GlaxoSmithKline, Janssen, MSD, Novartis, Pfizer, Nycomed, Roche and Servier. Conflict of interest: D. Dumitrescu declares honoraria for lectures and/or consultancy from Actelion, AstraZeneca, Bayer, GSK, Janssen, MSD, Novartis, Pfizer, Servier and Vifor. Conflict of interest: I. Tsangaris has received fees from Actelion, Bayer, ELPEN, GSK, Janssen, MSD, Pfizer and United Therapeutics. Conflict of interest: A. Vonk-Noordegraaf reports receiving fees for lectures and/or consultations from Actelion, Bayer, GlaxoSmithKline, Janssen, MSD and Pfizer. Conflict of interest: S. Ulrich reports personal fees from Actelion, Janssen and MSD outside the submitted work. Conflict of interest: H. Klose has received speaker fees and honoraria for consultations from Actelion, Bayer, GSK, Janssen, MSD, Novartis, Pfizer and United Therapeutics. Conflict of interest: M. Claussen reports honoraria for lectures from Boehringer Ingelheim Pharma GmbH and Roche Pharma, and for serving on advisory boards from Boehringer Ingelheim. Conflict of interest: T.J. Lange has received speaker fees and honoraria for consultation from Acceleron, Actelion, Bayer, GSK, Janssen-Cilag, MSD, Pfizer and United Therapeutics. Conflict of interest: S. Rosenkranz has received fees for lectures and/or consultations from Abbott, Acceleron, Actelion, Bayer, BMS, Gilead, GSK, Janssen, MSD, Novartis, Pfizer, United Therapeutics and Vifor; research grants to institution from AstraZeneca, Actelion, Bayer Janssen and Novartis., (Copyright ©The authors 2022.)
- Published
- 2022
- Full Text
- View/download PDF
48. Right atrial function is associated with right venticular diastolic stiffness: RA-RV interaction in pulmonary arterial hypertension.
- Author
-
Wessels JN, Mouratoglou SA, van Wezenbeek J, Handoko ML, Marcus JT, Meijboom LJ, Westerhof BE, Bogaard HJ, Strijkers GJ, Vonk Noordegraaf A, and de Man FS
- Subjects
- Atrial Function, Right, Diastole, Familial Primary Pulmonary Hypertension, Humans, Ventricular Function, Right, Hypertension, Pulmonary, Pulmonary Arterial Hypertension, Ventricular Dysfunction, Right
- Abstract
Background: Pulmonary arterial hypertension (PAH) patients have altered right atrial (RA) function and right ventricular (RV) diastolic stiffness. This study assessed the impact of RV diastolic stiffness on RA-RV interaction., Methods: PAH patients with low or high end-diastolic elastance (E
ed ) (n=94) were compared with controls (n=31). Treatment response was evaluated in 62 patients. RV and RA longitudinal strain, RA emptying and RV filling were determined and diastole was divided into a passive and active phase. Vena cava backflow was calculated as RA active emptying-RV active filling and RA stroke work as RA active emptying×RV end-diastolic pressure., Results: With increased Eed , RA and RV passive strain were reduced while active strain was preserved. In comparison to controls, patients had lower RV passive filling but higher RA active emptying and RA stroke work. RV active filling was lower in patients with high Eed , resulting in higher vena cava backflow. Upon treatment, Eed was reduced in ~50% of the patients with high Eed , which coincided with larger reductions in afterload, RV mass and vena cava backflow and greater improvements in RV active filling and stroke volume in comparison with patients in whom Eed remained high., Conclusions: In PAH, RA function is associated with changes in RV function. Despite increased RA stroke work, severe RV diastolic stiffness is associated with reduced RV active filling and increased vena cava backflow. In 50% of patients with high baseline Eed , diastolic stiffness remained high, despite treatment. A reduction in Eed coincided with a large reduction in afterload, increased RV active filling and decreased vena cava backflow., Competing Interests: Conflict of interest: J.N. Wessels has nothing to disclose. Conflict of interest: S.A. Mouratoglou has nothing to disclose. Conflict of interest: J. van Wezenbeek has nothing to disclose. Conflict of interest: M.L. Handoko has nothing to disclose. Conflict of interest: J.T. Marcus has nothing to disclose. Conflict of interest: L.J. Meijboom has nothing to disclose. Conflict of interest: B.E. Westerhof has nothing to disclose. Conflict of interest: H.J. Bogaard was supported by research grants from Actelion, GSK and Ferrer (Therabel). Conflict of interest: G.J. Strijkers has nothing to disclose. Conflict of interest: A. Vonk Noordegraaf was supported by research grants from Actelion, GSK and Ferrer (Therabel). Conflict of interest: F.S. de Man has nothing to disclose., (Copyright ©The authors 2022.)- Published
- 2022
- Full Text
- View/download PDF
49. Temporal trends in pulmonary arterial hypertension: results from the COMPERA registry.
- Author
-
Hoeper MM, Pausch C, Grünig E, Staehler G, Huscher D, Pittrow D, Olsson KM, Vizza CD, Gall H, Distler O, Opitz C, Gibbs JSR, Delcroix M, Ghofrani HA, Rosenkranz S, Park DH, Ewert R, Kaemmerer H, Lange TJ, Kabitz HJ, Skowasch D, Skride A, Claussen M, Behr J, Milger K, Halank M, Wilkens H, Seyfarth HJ, Held M, Dumitrescu D, Tsangaris I, Vonk-Noordegraaf A, Ulrich S, and Klose H
- Subjects
- Familial Primary Pulmonary Hypertension, Humans, Registries, Survival Rate, Hypertension, Pulmonary drug therapy, Hypertension, Pulmonary epidemiology, Pulmonary Arterial Hypertension drug therapy, Pulmonary Arterial Hypertension epidemiology
- Abstract
Background: Since 2015, the European pulmonary hypertension guidelines recommend the use of combination therapy in most patients with pulmonary arterial hypertension (PAH). However, it is unclear to what extent this treatment strategy is adopted in clinical practice and if it is associated with improved long-term survival., Methods: We analysed data from COMPERA, a large European pulmonary hypertension registry, to assess temporal trends in the use of combination therapy and survival of patients with newly diagnosed PAH between 2010 and 2019. For survival analyses, we looked at annualised data and at cumulated data comparing the periods 2010-2014 and 2015-2019., Results: A total of 2531 patients were included. The use of early combination therapy (within 3 months after diagnosis) increased from 10.0% in patients diagnosed with PAH in 2010 to 25.0% in patients diagnosed with PAH in 2019. The proportion of patients receiving combination therapy 1 year after diagnosis increased from 27.7% to 46.3%. When comparing the 2010-2014 and 2015-2019 periods, 1-year survival estimates were similar (89.0% (95% CI 87.2-90.9%) and 90.8% (95% CI 89.3-92.4%), respectively), whereas there was a slight but nonsignificant improvement in 3-year survival estimates (67.8% (95% CI 65.0-70.8%) and 70.5% (95% CI 67.8-73.4%), respectively)., Conclusions: The use of combination therapy increased from 2010 to 2019, but most patients still received monotherapy. Survival rates at 1 year after diagnosis did not change over time. Future studies need to determine if the observed trend suggesting improved 3-year survival rates can be confirmed., Competing Interests: Conflicts of interest: M.M. Hoeper has received fees for lectures and/or consultations from Acceleron, Actelion, Bayer, GlaxoSmithKline, Janssen, MSD and Pfizer. Conflicts of interest: C. Pausch has no disclosures. Conflicts of interest: E. Grünig has received fees for lectures and/or consultations from Actelion, Bayer, GlaxoSmithKline, Janssen, MSD, Pfizer and United Therapeutics. Conflicts of interest: G. Staehler has received honoraria for lectures and/or consultancy for Actelion, Bayer, GlaxoSmithKline, Novartis and Pfizer. Conflicts of interest: D. Huscher has received consulting fees from Actelion. Conflicts of interest: D. Pittrow has received fees for consultations from Actelion, Amgen, Aspen, Bayer, Biogen, Boehringer Ingelheim, Daiichi Sankyo, Sanofi, Takeda and Viatris. Conflicts of interest: K.M. Olsson has received fees for lectures and/or consultations from Acceleron, Actelion, Bayer, GlaxoSmithKline, Janssen, MSD, Pfizer and United Therapeutics. Conflicts of interest: C.D. Vizza has received fees for lectures and/or consultations from Acceleron, Actelion, Bayer, GlaxoSmithKline, Janssen, MSD, Pfizer and United Therapeutics. Conflicts of interest: H. Gall reports personal fees from Actelion, AstraZeneca, Bayer, BMS, GlaxoSmithKline, Janssen-Cilag, Lilly, MSD, Novartis, OMT, Pfizer and United Therapeutics. Conflicts of interest: O. Distler has/had consultancy relationship and/or has received research funding from 4D Science, Actelion, Active Biotec, Bayer, Biogen Idec, Boehringer Ingelheim Pharma, BMS, ChemoAb, EpiPharm, Ergonex, EspeRare Foundation, GlaxoSmithKline, Genentech/Roche, Inventiva, Janssen, Lilly, medac, MedImmune, Mitsubishi Tanabe, Pharmacyclics, Pfizer, Sanofi, Serodapharm and Sinoxa, in the area of potential treatments of scleroderma and its complications including PAH; in addition, the author has a patent “mir-29 for the treatment of systemic sclerosis” licensed. Conflicts of interest: C. Opitz has received speaker fees and honoraria for consultations from Actelion, Bayer, GlaxoSmithKline, Lilly, Novartis and Pfizer. Conflicts of interest: J.S.R. Gibbs has received fees for lectures and/or consultations from Acceleron, Actelion, Aerovate, Bayer, Complexia, Janssen, MSD, Pfizer and United Therapeutics. Conflicts of interest: M. Delcroix reports research grants from Actelion/J&J, speaker and consultant fees from Bayer, MSD, Acceleron, AOP and Daiichi Sankyo, outside the submitted work; and is holder of the Janssen Chair for Pulmonary Hypertension at the KU Leuven. Conflicts of interest: H.A. Ghofrani has received honoraria for consultations and/or speaking at conferences from Bayer HealthCare AG, Actelion, Encysive, Pfizer, Ergonex, Lilly and Novartis; is member of advisory boards for Acceleron, Bayer HealthCare AG, Pfizer, GlaxoSmithKline, Actelion, Lilly, Merck, Encysive and Ergonex; and has also received governmental grants from the German Research Foundation (DFG), Excellence Cluster Cardiopulmonary Research (ECCPS), State Government of Hessen (LOEWE) and the German Ministry for Education and Research (BMBF). Conflicts of interest: S. Rosenkranz has received fees for lectures and/or consultations from Abbott, Acceleron, Actelion, Bayer, BMS, Gilead, GlaxoSmithKline, Janssen, MSD, Novartis, Pfizer, United Therapeutics and Vifor; research grants to institution from AstraZeneca, Actelion, Bayer Janssen and Novartis. Conflicts of interest: D-H. Park has nothing to disclose. Conflicts of interest: R. Ewert has received speaker fees and honoraria for consultations from Actelion, Bayer, GlaxoSmithKline, Janssen, Lilly, MSD, Novartis, Pfizer and United Therapeutics. Conflicts of interest: H. Kaemmerer has received honoraria for lectures and/or consultancy from Actelion, BMS and Janssen. Conflicts of interest: T.J. Lange has received speaker fees and honoraria for consultation from Acceleron, Actelion, Bayer, GlaxoSmithKline, Janssen-Cilag, MSD, Pfizer and United Therapeutics. Conflicts of interest: H-J. Kabitz has received fees from Löwenstein Medical, Weinmann, Philips Respironics, ResMed, Vivisol, Sapio Life and Sanofi-Genzyme. Conflicts of interest: D. Skowasch received fees for lectures and/or consulting and/or research support to institution from Actelion, Bayer, GlaxoSmithKline, Janssen, MSD and Pfizer. Conflicts of interest: A. Skride reports no conflicts of interest. Conflicts of interest: M. Claussen reports honoraria for lectures from Boehringer Ingelheim Pharma GmbH and Roche Pharma, and for serving on advisory boards from Boehringer Ingelheim. Conflicts of interest: J. Behr received grants from Actelion, Bayer, Biogen, Boehringer Ingelheim, Galapagos, Novartis, Roche and Sanofi/Genzyme. Conflicts of interest: K. Milger has received fees from Actelion, AstraZeneca, GlaxoSmithKline, Janssen, MSD, Novartis and Sanofi-Aventis. Conflicts of interest: M. Halank has received speaker fees and honoraria for consultations from Acceleron, Actelion, AstraZeneca, Bayer, BerlinChemie, GlaxoSmithKline, Janssen and Novartis. Conflicts of interest: H. Wilkens received personal fees from Actelion, Bayer, Biotest, Boehringer, GlaxoSmithKline, Janssen, Pfizer and Roche. Conflicts of interest: H-J. Seyfarth has received speaker fees and honoraria for consultations from Actelion, Bayer, GlaxoSmithKline, Janssen and MSD. Conflicts of interest: M. Held has received speaker fees and honoraria for consultations from Actelion, Bayer, Boehringer Ingelheim Pharma, GlaxoSmithKline, Janssen, MSD, Novartis, Pfizer, Nycomed, Roche and Servier. Conflicts of interest: D. Dumitrescu declares honoraria for lectures and/or consultancy from Actelion, AstraZeneca, Bayer, GlaxoSmithKline, Janssen, MSD, Novartis, Pfizer and Servier. Conflicts of interest: I. Tsangaris has received fees from Actelion, Bayer, ELPEN, GlaxoSmithKline, Janssen, MSD, Pfizer and United Therapeutics. Conflicts of interest: A. Vonk-Noordegraaf reports receiving fees for lectures and/or consultations from Actelion, Bayer, GlaxoSmithKline, Janssen, MSD and Pfizer. Conflicts of interest: S. Ulrich reports personal fees from Actelion, Janssen and MSD outside the submitted work. Conflicts of interest: H. Klose has received speaker fees and honoraria for consultations from Actelion, Bayer, GlaxoSmithKline, Janssen, MSD, Novartis, Pfizer and United Therapeutics., (Copyright ©The authors 2022.)
- Published
- 2022
- Full Text
- View/download PDF
50. ERS statement on chronic thromboembolic pulmonary hypertension.
- Author
-
Delcroix M, Torbicki A, Gopalan D, Sitbon O, Klok FA, Lang I, Jenkins D, Kim NH, Humbert M, Jais X, Vonk Noordegraaf A, Pepke-Zaba J, Brénot P, Dorfmuller P, Fadel E, Ghofrani HA, Hoeper MM, Jansa P, Madani M, Matsubara H, Ogo T, Grünig E, D'Armini A, Galie N, Meyer B, Corkery P, Meszaros G, Mayer E, and Simonneau G
- Subjects
- Chronic Disease, Endarterectomy, Humans, Pulmonary Artery, Angioplasty, Balloon, Hypertension, Pulmonary, Pulmonary Embolism
- Abstract
Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare complication of acute pulmonary embolism, either symptomatic or not. The occlusion of proximal pulmonary arteries by fibrotic intravascular material, in combination with a secondary microvasculopathy of vessels <500 µm, leads to increased pulmonary vascular resistance and progressive right heart failure. The mechanism responsible for the transformation of red clots into fibrotic material remnants has not yet been elucidated. In patients with pulmonary hypertension, the diagnosis is suspected when a ventilation/perfusion lung scan shows mismatched perfusion defects, and confirmed by right heart catheterisation and vascular imaging. Today, in addition to lifelong anticoagulation, treatment modalities include surgery, angioplasty and medical treatment according to the localisation and characteristics of the lesions.This statement outlines a review of the literature and current practice concerning diagnosis and management of CTEPH. It covers the definitions, diagnosis, epidemiology, follow-up after acute pulmonary embolism, pathophysiology, treatment by pulmonary endarterectomy, balloon pulmonary angioplasty, drugs and their combination, rehabilitation and new lines of research in CTEPH.It represents the first collaboration of the European Respiratory Society, the International CTEPH Association and the European Reference Network-Lung in the pulmonary hypertension domain. The statement summarises current knowledge, but does not make formal recommendations for clinical practice., Competing Interests: Conflict of interest: M. Delcroix reports grants and other (investigator, speaker and consultant fees received by the institution) from Actelion/J&J, other (investigator, speaker and consultant fees received by the institution) from Bayer, other (speaker and consultant fees received by the institution) from MSD, other (investigator fees received by the institution) from Reata, other (investigator and consultant fees received by the institution) from Bellarophon, other (consultant fees received by the institution) from Acceleron, outside the submitted work. Conflict of interest: A. Torbicki reports grants and personal fees for lectures and consultancy from Actelion/Janssen, Bayer and MSD, personal fees for lectures from AOP, personal fees for lectures and consultancy from Pfizer, outside the submitted work. Conflict of interest: D. Gopalan reports other (speaker fees) from Actelion/J&J, other (consultancy work and speaker fees) from Bayer, outside the submitted work. Conflict of interest: O. Sitbon reports grants, personal fees and non-financial support from Actelion Pharmaceuticals and MSD, grants from GlaxoSmithKline, personal fees from Bayer, Acceleron Pharmaceuticals, Gossamer Bio and Ferrer, outside the submitted work. Conflict of interest: F.A. Klok reports research grants from Bayer, Bristol-Myers Squibb, Boehringer Ingelheim, Daiichi-Sankyo, MSD and Actelion, the Dutch Heart Foundation and the Dutch Thrombosis association, outside the submitted work. Conflict of interest: I. Lang reports grants and personal fees from Actelion-Janssen and AOP Orphan Pharma, personal fees from Medtronic, Ferrer and United Therapeutics, outside the submitted work. Conflict of interest: D. Jenkins reports grants from Bayer, personal fees for advisory board work from Actelion, outside the submitted work. Conflict of interest: N.H. Kim reports personal fees for consultancy from Actelion, Bayer and Merck, outside the submitted work. Conflict of interest: M. Humbert reports grants and personal fees from Actelion and Bayer, personal fees from Acceleron, GSK, Merck, Novartis, AstraZeneca and Sanofi, outside the submitted work. Conflict of interest: X. Jais reports personal fees and non-financial support from Actelion and MSD, grants from Bayer, outside the submitted work. Conflict of interest: A. Vonk Noordegraaf is supported by the Netherlands CardioVascular Research Initiative (CVON-2012-08 PHAEDRA, CVON-2017-10 DOLPHIN-GENESIS) and the Netherlands Organization for Scientific Research (NWO-VICI: 918.16.610), has received speakers’ money from Johnson & Johnson and Ferrer in the past 3 years, and served as a member of the scientific advisory board of Morphogen-XI. Conflict of interest: J. Pepke-Zaba has received speaker fees and honoraria for consultations from Actelion, Merck and Bayer, and her institution received research and educational grants from Actelion and Merck. Conflict of interest: P. Brénot has nothing to disclose. Conflict of interest: P. Dorfmuller has nothing to disclose. Conflict of interest: E. Fadel has nothing to disclose. Conflict of interest: H-A. Ghofrani reports personal fees and other (consultancy fees) from Actelion, Bayer AG, GlaxoSmithKline, Novartis and Pfizer, other (consultancy fees) from Bellerophon Pulse Technologies and MSD, grants from Deutsche Forschungsgemeinschaft (DFG), during the conduct of the study. Conflict of interest: M.M. Hoeper reports personal fees for consultancy and lectures from Bayer AG, MSD, Actelion, Jansen, Acceleron and Pfizer, during the conduct of the study. Conflict of interest: P. Jansa reports other (investigator) from Actelion, personal fees and other (investigator) from Bayer Pharma AG and Reata Pharmaceuticals, personal fees from AOP and MSD, outside the submitted work. Conflict of interest: M. Madani reports personal fees for consultancy from Actelion and Wexler Surgical, outside the submitted work. Conflict of interest: H. Matsubara reports personal fees from Actelion Pharmaceuticals Japan, Ltd, AOP Orphan Pharmaceuticals AG, Bayer Yakuhin, Ltd, Pfizer Japan, Inc., Nippon Shinyaku, Co., Ltd, Kaneka Medix Corporation, GlaxoSmithKline Pharmaceuticals, Ltd and United Therapeutics Corporation, outside the submitted work. Conflict of interest: T. Ogo has nothing to disclose. Conflict of interest: E. Grünig reports fees for lectures and/or consultations from Actelion, Bayer AG, GSK, MSD, United Therapeutics and Pfizer, outside the submitted work. Conflict of interest: A. D'Armini reports personal fees from Actelion Phamaceuticals, Bayer AG and Merck Sharp & Dohme, outside the submitted work. Conflict of interest: N. Galie reports grants and personal fees from Actelion and Janssen, personal fees from Pfizer and Ferrer, outside the submitted work. Conflict of interest: B. Meyer reports personal fees for lectures from Bayer AG, outside the submitted work. Conflict of interest: P. Corkery has nothing to disclose. Conflict of interest: G. Meszaros reports personal fees from Actelion Pharmaceuticals, outside the submitted work. Conflict of interest: E. Mayer reports personal fees for lectures and consultancy from Actelion, Bayer and MSD, during the conduct of the study. Conflict of interest: G. Simonneau reports personal fees and non-financial support from Actelion, Bayer and MSD, outside the submitted work., (Copyright ©ERS 2021. For reproduction rights and permissions contact permissions@ersnet.org.)
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.